Trial reportCancer immunology, immunotherapy : CII2006
Dendritic cell-based cancer immunotherapy targeting MUC-1.
Trial report in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 73 citations in OpenAlex.
- Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Trial
- Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Trial
- Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.Clinical and vaccine immunology : CVI · 2008Trial
- Research progress of MUC1 in genitourinary cancers.Cellular & molecular biology letters · 2024Review
- Overexpression of tousled-like kinase 2 predicts poor prognosis in HBV-related hepatocellular carcinoma patients after radical resection.Frontiers in genetics · 2023Article
- The mononuclear phagocyte system in hepatocellular carcinoma.World journal of gastroenterology · 2022Review
- Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients.Frontiers in immunology · 2019Article
- EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells.PloS one · 2018Article
- Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis.World journal of urology · 2016Article
- Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases.Glycoconjugate journal · 2015Review
- Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Article
- Trial watch: Dendritic cell-based interventions for cancer therapy.Oncoimmunology · 2012Article
- Multidimensional glycan arrays for enhanced antibody profiling.Molecular bioSystems · 2010Article
- Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.Clinical & developmental immunology · 2010Review
- Immunotherapy for renal cell carcinoma.Clinical & developmental immunology · 2010Article
- Mucins in ovarian cancer diagnosis and therapy.Journal of ovarian research · 2009Article
- Immune responses of human immature dendritic cells can be modulated by the recombinant Aspergillus fumigatus antigen Aspf1.Clinical and vaccine immunology : CVI · 2009Article
- HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.Neoplasia (New York, N.Y.) · 2008Article
- Dendritic cell vaccination and other strategies to tip the balance of the immune system : DC2007 5th International Meeting, July 16-18, Bamberg, Germany.Cancer immunology, immunotherapy : CII · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination therapy using dendritic cells (DC) as antigen presenting cells (APC) has shown significant promise in laboratory and animal studies as a potential treatment for malignant diseases. Pulsing of autologous DCs with tumor-associated antigens (TAA) is a method often used for antigen delivery and choice of suitable antigens plays an important role in designing an effective vaccine. We identified two HLA-A2 binding novel 9-mer peptides of the TAA MUC1, which is overexpressed on various hematological and epithelial malignancies. Cytotoxic T cells generated after pulsing DC with these peptides were able to induce lysis of tumor cells expressing MUC1 in an antigen-specific and HLA-restricted fashion. Within two clinical studies, we demonstrated that vaccination of patients with advanced cancer using DCs pulsed with MUC1 derived peptides is well tolerated without serious side effects and can induce immunological responses. Of 20 patients with metastatic renal cell carcinoma, 6 patients showed regression of metastases with 3 objective responses (1 CR, 2 PR). Furthermore, we found that in patients responding to treatment T cell responses for antigens not used for treatment occurred suggesting that antigen spreading in vivo might be a possible mechanism of mediating antitumor effects. These results demonstrate that immunotherapy in patients with advanced malignancies using autologous DCs pulsed with MUC1 derived peptides can induce immunological and clinical responses. However, further clinical studies are needed to identify the most potent treatment regimen that can consistently mediate an antitumor immune response in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.